Washington, D.C. 20549









Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934


August 5, 2020




 (Exact name of Registrant as specified in its charter)



Novo Allé 

DK- 2880, Bagsvaerd 


(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F


Form 20-F [X]           Form 40-F [  ]


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


Yes [  ]            No [X]


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________








Novo Nordisk A/S – Share repurchase programme



Bagsværd, Denmark, 5 August 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.


Under the programme, initiated 11 May 2020, Novo Nordisk has repurchased B shares for an amount up to DKK 2.6 billion in the period from 12 May 2020 to 4 August 2020. The programme is now concluded.


Since the announcement as of 28 July 2020, the following transactions have been made:


  Number of
B shares
purchase price
value, DKK
Accumulated, last announcement 5,359,150   2,338,027,461
28 July 2020 103,000 428.15 44,099,961
29 July 2020 101,000 427.21 43,148,533
30 July 2020 103,000 424.48 43,720,976
31 July 2020 103,000 420.82 43,344,297
3 August 2020 103,000 414.21 42,663,250
4 August 2020 109,810 409.76 44,995,285
Accumulated under the programme 5,981,960   2,599,999,763


The details for each transaction made under the share repurchase programme are published on novonordisk.com.




Page 2 of 2



With the transactions stated above, Novo Nordisk owns a total of 20,063,980 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.


Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12- month period beginning 5 February 2020. As of 4 August 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 20,059,179 B shares at an average share price of DKK 426.28 per B share equal to a transaction value of DKK 8,550,787,732.



Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.



Further information

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Mark Joseph Root +45 3079 4211 mjhr@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com









Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd



+45 4444 8888


CVR no:

24 25 67 90

    Company announcement No 48 / 2020





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.


Date: August 5, 2020




Lars Fruergaard Jørgensen

Chief Executive Officer